接受治疗的发作发生的主要部位为四肢68次，面部48次，胃肠道272次，泌尿生殖系统9次，喉50次。
The primary location of the treated attacks was the extremities in 68 patients, facial in 48, gastrointestinal in 272, genitourinary in 9, and laryngeal in 50.
选择性的CB1受体阻滞剂通过作用该受体，具有治疗肥胖、 酒精依赖、 尼古丁成瘾、认知障碍以及胃肠道系统疾病等作用。
Selective CB1-R antagonists have potential in the treatment of a number of diseases, such as obesity, alcohol dependence, nicotine addiction, cognitive disorders, and gastrointestinal disorders.
应用推荐